Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab vs Placebo After Resection of Esophageal or Gastroesophageal Junction Cancer
jRCT2080223354Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and esophagogastric junction cancer comparing Adjuvant nivolumab with Adjuvant placebo (2 arms). Started Oct 2016; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080223354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223354.